Background-In rural areas in China and India, the cardiovascular disease burden is high but economic and healthcare resources are limited. This study (the Simplified Cardiovascular Management Study [SimCard]) aims to develop and evaluate a simplified cardiovascular management program delivered by community health workers with the aid of a smartphone-based electronic decision support system. Methods and Results-The SimCard study was a yearlong cluster-randomized, controlled trial conducted in 47 villages (27 in China and 20 in India). Recruited for the study were 2086 individuals with high cardiovascular risk (aged ≥40 years with self-reported history of coronary heart disease, stroke, diabetes mellitus, and/or measured systolic blood pressure ≥160 mm Hg). Participants in the intervention villages were managed by community health workers through an Android-powered app on a monthly basis focusing on 2 medication use and 2 lifestyle modifications. In comparison with the control group, the intervention group had a 25.5% (P<0.001) higher net increase in the primary outcome of the proportion of patient-reported antihypertensive medication use pre-and post-intervention. There were also significant differences in certain secondary outcomes: aspirin use (net difference: 17.1%; P<0.001) and systolic blood pressure (-2.7 mm Hg; P=0.04). However, no significant changes were observed in the lifestyle factors. The intervention was culturally tailored, and country-specific results revealed important differences between the regions. 
C ardiovascular diseases (CVDs) are one of the leading causes of morbidity, mortality, and disability in both high-income and low-and middle-income countries. 1 In 2011, it accounted for 41% and 29% of the total deaths, respectively, in China and India, 2,3 2 of the largest growing economies in the world. They also face similar challenges and opportunities in CVD prevention and control such as the rising CVD burden, large urban-rural health disparities, limited resources and capacity, a large population base, and increasing access to mobile phones. Although differences also exist in the healthcare systems, socioeconomic environment, and culture customs between China and India, there is a need to jointly evaluate cost-effective and sustainable strategies for CVD prevention in the rural areas of both countries. Clinical guidelines, built on ample scientific evidence, recommend a combined strategy of lifestyle modifications and appropriate medication use for CVD prevention and control, based on a high-risk approach, ie, to identify and manage individuals at high CVD risk. [4] [5] [6] [7] [8] [9] [10] Targeting high-risk individuals would be potentially a highly cost-effective approach, especially for resource-limited settings. Reliance on the overburdened and relatively small number of specialists to implement this strategy is not feasible or sustainable. Previous studies have shown that there are significant improvements in accessing healthcare facilities, disease screening and monitoring, and patients' adherence to treatment by engaging community healthcare workers (CHWs). [11] [12] [13] [14] In addition, to build capacity and ensure the quality of implementation, the intervention needs to be simplified and tailored to the local contexts and adequate training and technical support needs to be provided to CHWs. The high penetration of cell phones even in resourcepoor settings offers an unprecedented opportunity to provide such support to CHWs in CVD prevention and control.
Therefore, this study aims to develop and evaluate a simplified yet guideline-based multifaceted intervention program for cardiovascular management among individuals with high cardiovascular risk delivered by CHWs with the aid of a mobile technology-based electronic decision support system (EDSS) in rural China and India (the Simplified Cardiovascular Management Study [SimCard] ).
Methods

Study Design
The SimCard study is a single-blinded cluster-randomized, controlled trial conducted in rural villages in Tibet Autonomous Region (hereafter, Tibet), China, and Haryana, India. This trial was coordinated by the George Institute for Global Health at Peking University Health Science Center in collaboration with Tibet University in China and the Public Health Foundation of India in India. Ethical approval of the study protocol was granted by the institutional review boards at Peking University Health Science Center, China, Public Health Foundation of India, and Duke University, USA. Written informed consents were obtained from all participants. We describe the study design below, in brief, with more details available in the published protocol. 15 
Study Sites and Participants
This trial was conducted in 27 villages from 15 townships (the administrative unit managing the village) in 2 counties of Tibet, China and 20 villages from 1 tehsil (an administrative unit for a group of villages) in Haryana State, India. The 2 regions are geographically close to each other with Tibet to the east and Haryana to the west of the Himalayan Mountains. Tibet lies in southwest China and has a population of 3 million. The 2 counties, Gongbujiangda County and Linzhou County, are located in the eastern and central parts of Tibet, respectively. Gongbujiangda County has jurisdiction over 9 townships with a total of 80 villages, and Linzhou County has jurisdiction over 10 townships with a total of 45 villages. In India, this trial was conducted in Ballabgarh tehsil (subdistrict) of District Faridabad in the north Indian state of Haryana. There are 82 villages in Ballabgarh. Villages from both countries were chosen based on the eligibility criteria of having (1) within high CVD burden region, (2) limited healthcare resources, (3) existing CHWs or qualified candidates who can be trained to fulfill their role, and (4) local government support. The average population size of the villages in the trial was 900 in China and 3500 in India, respectively.
Inclusion criteria for the participants include being residents in the participating villages and having high cardiovascular risk (high-risk hereafter). For ease of operation, high-risk in this study was defined on the basis of age, disease history, and measured blood pressure. Thus, individuals who were ≥40 years of age with a self-reported history of (1) coronary heart disease, (2) stroke, (3) diabetes mellitus, and/or (4) measured systolic blood pressure (SBP) ≥160 mm Hg were included in the study. Exclusion criteria were as follows: (1) having CVD-related complications that cannot be managed in a primary care setting; (2) having a malignancy or life-threatening disease; (3) individuals who are bed-ridden; (4) currently participating in any other clinical trials; and (5) unable to stay in the village longer than 8 months out of a year. Blood pressure was measured twice by a trained interviewer using a validated Omron HEM-7201 automatic blood pressure monitor (Omron Healthcare, Kyoto, Japan). At baseline, all age-eligible participants were screened by a brief questionnaire and blood pressure measurement. Only participants who were identified as high risk were enrolled into the trial.
Randomization
Villages were randomly assigned to intervention or control with stratification by country. In China, 27 villages were randomly assigned to the intervention and control group with stratification by county and township. Villages in India were randomly assigned without any stratification. A study-independent staff generated the randomization pattern through a central computerized process.
Intervention
The intervention was developed and simplified based on the international and national clinical guidelines for CVD management. [16] [17] [18] [19] The key elements of the intervention were summarized as a 2+2 model, which consisted of 2 therapeutic lifestyle modifications (smoking cessation and salt reduction) and the appropriate prescription of 2 medications (blood pressure-lowering agents and aspirin). For blood pressure-lowering, the agent was low-dose hydrochlorothiazide, 12.5 mg/d in China, and calcium-channel blocker, 2.5 or 5 mg/d in India. The recommended dose for aspirin was 75 to 100 mg/d. All drugs were generally safe, low cost, and locally available. All hypertensive patients (SBP ≥140 mm Hg) without contraindications would be prescribed the antihypertensive medication with a treatment target of ≤140 mm Hg whereas only patients with coronary heart disease, ischemic stroke, and diabetes mellitus, but without contraindications such as bleeding or high blood pressure (SBP ≥160 mm Hg) would be prescribed aspirin. The intervention model was designed to target the prevalent risk factors associated with CVD in these 2 areas. It was also designed to be easily implemented and incorporated into the existing local healthcare system.
In rural China, CHWs are village doctors who are not physicians but have received basic health professional training and are able to prescribe medications. In India, the CHWs were volunteer members of the community and not authorized to prescribe medicine. They were supported by a partnership with licensed physicians in healthcare centers responsible for providing clinical guidance and prescribing medications. The management program was delivered by trained CHWs in the intervention group on a monthly basis with the assistance of EDSS in the form of an Android-based app installed on smartphones. The development of the EDSS in this study was based on the 2+2 intervention model and with easy acceptance and usability by the CHWs in mind to ensure successful implementation of the intervention. It consisted of prompts regarding the patient's current lifestyle habits, blood pressure measurements, current medication use, previous medical history, new conditions, contraindications, and side effects. In India, the EDSS had a desktop component for the use by guest on April 14, 2017 http://circ.ahajournals.org/ Downloaded from of physicians to approve the drugs as suggested by the smartphonebased EDSS for CHWs.
Before the start of the intervention, all CHWs in the intervention group received initial 1-day systematic training. After the training was provided, CHWs received the list of the participants who were identified as high risk at baseline in their villages. CHWs were instructed to provide monthly follow-up visits for the high-risk participants under their management. These visits were conducted either in village clinics or another central place in the village or patient homes and included screening for new symptoms, diseases, and side effects since the last visit, measuring blood pressure, providing lifestyle counseling, and, when appropriate, prescribing 1 or both medications. CHWs received refresher training every 3 to 4 months during the implementation of the intervention.
In both China and India, interventions were tailored to the local cultures and customs when possible. For example, special education was provided to alleviate concerns among Tibetan patients against western medicines. Health educational materials on lifestyle in China and India were all provided in local languages with culture-specific images. Performance feedback and performancebased incentives to the CHWs were also part of the intervention package in China, whereas Indian CHWs received fixed monthly honorariums. On average, the payment for CHWs in the intervention group for the entire duration of the intervention was US$400 in China and US$500 in India. The duration of the trial was designed to be 1 year.
In the control group, the usual cardiovascular management programs continued without additional intervention. However, in India, as stipulated by the ethics committee, the medications used in the intervention arm were also made available free of charge to patients in the primary care facilities serving the control villages, typically located 15 to 40 minutes by motorcycle from the villages. The main differences in implementation of the study in 2 countries are summarized in Table 1 .
Outcomes
The primary outcome was the net difference between groups in the change in the proportion of patient-reported antihypertensive medication use from baseline to 1-year follow-up.
A number of secondary outcomes were also evaluated to fully capture the effects of the intervention. The main secondary outcomes included between-group differences in the changes from baseline to 1-year follow-up in (1) the proportion of high-risk individuals taking aspirin, (2) the mean systolic blood pressures of high-risk individuals, (3) the proportion of current smokers, (4) the proportion of high-risk individuals aware of the harms of a high-salt diet, (5) the proportion of high-risk individuals receiving monthly follow-ups from the CHWs, and (6) the proportion of high-risk individuals hospitalized.
The outcomes were assessed with data collected during baseline and post intervention surveys from all high-risk individuals in both intervention and control villages in a standardized manner. The 2 survey questionnaires were identical and included information on demographics, lifestyle behaviors, medical care, medication use, and other relevant information. A few questions, such as about smoking, were different between the Chinese and Indian questionnaires to reflect the actual patterns in each country. Height, weight, waist circumference, and blood pressure were also measured according to standardized procedures in both surveys.
Sample Size
This study was powered on the primary outcome, the proportion of high-risk individuals taking antihypertensive medication. In the design stage, we calculated the sample size based on the assumption of 2000 high-risk individuals in 40 clusters (20 intervention villages and 20 control villages), an intracluster correlation coefficient of 0.02 and a 2-sided α of 0.05. 14, 20 The study had >90% power to detect a 10% net difference in the primary outcome. For the secondary outcome of SBP, assuming a standard deviation of the change in SBP of 15 mm Hg among high-risk individuals, the study also had excellent power (>90%) to detect a 3 mm Hg net difference with an intracluster correlation coefficient of 0.02.
Statistical Analysis
All analyses on outcomes were at the individual level but accounted for clustering and were conducted under the principle of intention-to-treat.
Table 1. System and Project-Level Differences in Study Implementation Between China and India, SimCard Study
Level
China India
Healthcare system CHWs are village doctors who are not physicians but received basic health professional training and are able to prescribe medicines.
CHWs are volunteers from the community and not authorized to prescribe medicines. They are supported by a partnership with licensed physicians in healthcare centers responsible for providing clinical guidance and prescribing medications.
Participant recruitment Trained medical students from Tibet University consented all ageeligible participants in the selected villages and screened them for high cardiovascular risk. Participants who were identified as high cardiovascular risk were enrolled into the study.
CHWs visited all households in the selected villages and approached all age-eligible participants for eligibility check. Eligible participants were invited to attend a medical camp in the village. During the camp, a qualified physician examined the participants and enrolled them into the study after obtaining informed consent.
Intervention (country-specific adaptations made to suit local contexts)
1.CHWs were aided by the smartphone-based EDSS to prescribe appropriate medication and lifestyle counseling during the monthly follow-up. For the primary outcome, the proportion of high-risk individuals treated with antihypertensive medication, a mixed logistic model with 2 sets of random intercepts -for the village, to account for the clustered study design, and for individuals nested within the village, to account for the 2 outcome measurements on the same individual -was used, and an unstructured covariance matrix structure was specified. All models included fixed effects for group (intervention versus control), time (follow-up versus baseline) and the groupby-time interaction. The model-based P value associated with the interaction term was used to test a net difference in change (from baseline to follow-up) between groups. The descriptive data for each group and the net difference in change for each outcome were obtained from raw data. Analyses of other dichotomous outcomes adopted the same analytic model as the primary outcome. In case models failed to converge, other variance-covariance structures that produced convergence were used. For the continuous outcome of SBP, similar modeling strategies were adopted, but mixed linear models instead of mixed logistic models were used.
Considering the potential cultural diversity across the 2 countries, prespecified subgroup analyses by country were performed on all outcomes. The analyses were conducted by using SAS software package (Version 9.3, SAS Institute Inc, Cary, NC). All P values provided were from models without adjusting for any individual characteristics.
Results
Patient recruitment started in January 2012, and the last patient completed the study in March 2014. Of the 52 potential villages assessed for eligibility in the study, 5 were excluded because many residents in the villages were nomadic herdsmen who did not meet the criteria of staying in the villages at least 8 months in a year (Figure 1 ). In the remaining 47 villages surveyed, 2086 individuals were identified as highrisk and recruited for the purposes of this study, with 23 villages (1095 high-risk individuals) randomly assigned to the intervention group and 24 villages (991 high-risk individuals) randomly assigned to the usual care (control) group. Eightyeight percent of individuals (1828) at high risk were successfully followed up at the end of the study. Loss to follow-up was similar between the intervention (12.1%) and control (12.6%) groups.
Baseline Characteristics
Baseline demographic and clinical characteristics of participants are provided in Table 2 . The typical participant across both countries was a 60-year-old illiterate woman. In China, there were no statistical differences between subjects in the intervention group in comparison with those in the control group. In India, with the exceptions of the history of coronary heart disease (P<0.001) and history of diabetes mellitus (P=0.004), no significant differences were found.
Primary Outcome
The intracluster correlation coefficient at baseline for the primary outcome of patient-reported antihypertensive medication use was 0.02. Preintervention use of antihypertensive medication was low (<7%) in both groups and in both countries (Figure 2 ). After the intervention, the proportion increased dramatically in the intervention group, reaching 36.3%, with a net pre-post difference between the 2 groups of 25.5% (P<0.001). The interaction between the countries on the primary outcome was significant (P<0.01). Countryspecific difference was further explored. The net difference in China was 24.4% and, in India, the net difference was 26.6%; both were highly statistically significant between the intervention and control groups. These outcomes used all high-risk individuals as the denominator to show the overall impact. Intention to treat analysis: 1,095 were analyzed.
Intention to treat analysis: 991 were analyzed. We conducted additional analyses on the primary outcome by using only the subgroup of hypertensive patients identified at baseline (n=1582). Results were similar (P<0.001) with net differences of 27%, 24%, and 31% for the combined, China, and India data, respectively.
Secondary Outcomes
In the analyses combining results from both countries, there was a significant net increase in the proportion of high-risk individuals taking aspirin (17.1%, P<0.001) and a significant reduction in mean SBP (-2.7 mm Hg, P=0.04). Interaction between the countries on those variables was significant (P<0.01 and P<0.05, respectively). In the country-specific analysis, the net increase in the proportion of high-risk individuals taking aspirin was higher in China (24.5%) than in India (9.8%), but both were highly significant (P<0.01; Table 3 ).
There was a significant net reduction in mean SBP in China (-4.1 mm Hg, P=0.006) but a nonsignificant decline in India. Both countries had large net increases (>16%) in the proportion of high-risk patients receiving monthly follow-up, but the statistical significance was different for China (P<0.001) and India (P=0.20). We did not observe any change in tobacco use or knowledge of the harmful effects of high-salt intake in the combined results.
Additional Analyses
We conducted additional analyses to adjust for baseline variables with significant differences between the intervention and control group (namely, history of coronary heart disease and diabetes mellitus in India). Such adjustments made no appreciable or negligible changes in the magnitude or P values for the primary or secondary outcomes. To further investigate the influence of loss to follow-up on the results, we compared all 15 available baseline characteristics between the subjects who were followed up and those lost to follow-up. We found that there were significant differences in 3 variables: age, body mass index, and sex; however, the absolute differences for these variables were not large ( Table I in the onlineonly Data Supplement: 1.9 years for age, 0.9 kg/m 2 for body mass index) with little effect on the outcomes in the adjusted model (detailed results not shown). As a sensitivity analysis, we excluded 1 site (the only site) with a loss to follow-up rate >30% and reran the analyses. The new results showed little effect on the main findings.
Discussion
Summary of Findings
The combined results from China and India, and countryspecific results in the SimCard trial, as well, provided clear 
Simplified and Multifaceted High-Risk Intervention Strategy
Both population-based and high-risk strategies are necessary for CVD prevention and control. In resource-poor settings, it is a cost-effective choice to adopt a high-risk approach first and is in line with clinical guidelines on CVD prevention and management. In addition, a comprehensive and integrated approach combining drug therapies and lifestyle modifications as opposed to strategies targeting single risk factors is required. 18, [21] [22] [23] [24] [25] In this trial, the intervention focused on 2 lifestyle factors (smoking cessation and sodium reduction) and 2 low-cost and generally safe medications with demonstrated effects on risk reduction. As designed, the intervention was more simplified than all clinical guidelines, including those for primary care, to suit the contexts of our study sites and to ensure the quality of implementation and sustainability in the long run. 16, 18, 19, [26] [27] [28] Nonetheless, it was a multifaceted approach and, if implemented successfully, was relevant to not only CVD, but also to other chronic diseases affected by these lifestyle factors and hypertension. We found that the intervention was effective in changing physician behaviors, including appropriate medication prescription, regular followup and lifestyle counseling, and patient behavior in terms of medication use, as well, but not actual patient lifestyle changes. Country-specific analyses showed that reduction in blood pressure was evident in China only, and, even in China, the magnitude (4.1 mm Hg) was modest, potentially owing to the use of the low-dose single-drug regimen only.
Role of CHWs
Our study was designed on the basis of previous studies demonstrating the potential effectiveness of CHWs in shifting and sharing the tasks of healthcare professionals in maternal and child health and chronic disease prevention and control. [11] [12] [13] [14] 29 In particular, the SimCard trial learned lessons from and adapted the intervention program in the Rural Andhra Pradesh Pre-intervention Post-intervention : Anti-hypertensive medication use in the past month is defined as self-reported use of CHW-prescribed antihypertensive medication with ≥ 25 days in the past month.
# : The interaction between China and India was significant (P<0.01).
*: P-value for the net difference of pre-and-post intervention between the groups Figure 2 . Effect of the simplified management program on the primary outcome among high-risk individuals. ^Antihypertensive medication use in the past month is defined as self-reported use of community healthcare workers-prescribed antihypertensive medication for ≥25 days in the past month.
# The interaction between China and India was significant (P<0.01). *P value for the net difference of pre-and post intervention between the groups. by guest on April 14, 2017 http://circ.ahajournals.org/ Downloaded from Cardiovascular Prevention Study in India and the China Rural Health Initiative. [29] [30] [31] Both studies targeted individuals with high cardiovascular risk and implemented an intervention package delivered by CHWs. The main innovations in the present study were further simplifications of the intervention into the 2 (lifestyle factors) + 2 (medications) model to suit the local contexts of more limited resources and capacity and the adoption of mobile health technology. Our results are generally consistent with previous studies in demonstrating the effectiveness of context-specific, culturally appropriate intervention delivered by CHWs on certain indicators such as medication use, but not on others such as lifestyle improvement.
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Use of Mobile Health Technology
In our study, we used the mobile phone-based EDSS to assist the CHWs in following up their high-risk individuals on a monthly basis. The use of mobile health technology was primarily in the form of an Android-based app installed on smartphones for assisting the CHWs in the intervention group for the appropriate prescription of drugs and for the provision of lifestyle recommendations. The use of EDSS was crucial in providing a centralized outlet of patient information database and guidance for a more efficient and appropriate administration of care by the CHWs. Although the trial was not designed to differentiate the impacts of the specific components of the intervention, it is conceivable that EDSS plays an important role in our finding of a positive effect on chronic disease management through reducing CHW training time, providing standardized evidence-based management plan, and enhancing user satisfaction. [32] [33] [34] The EDSS can be further improved by integrating user-centered design, linking with a local electronic health record system, and engaging the patients to interact with the CHWs.
Interpretation of Findings in China and India
China and India had similar results in certain outcomes, such as increases in medication prescriptions, and different patterns in other indicators including blood pressure, as well. These findings may be explained by some important differences between the 2 countries in study implementation. First, although both regions had high disease burdens, the prevalence of hypertension among adults ≥18 years was higher in Tibet, China (51%) than in Haryana, India (25%) according to previous surveys. 35, 36 In the present trial, baseline SBP was ≈10 mm Hg higher in Tibet than in Haryana, which may potentially partially explain the larger reduction in SBP observed in Tibet from increased medication use. Second, the CHWs in India were not authorized to prescribe medications and could therefore only serve as motivators for increasing compliance. They were volunteers provided with fixed honorariums instead of performance-based incentives. Third, because of ethical stipulations made by the review board in India, the 2 types of medications used in the intervention were also made readily available free of charge to the control groups. As such, the participants in the control group who were more inclined to proactively seek care from the health facilities after baseline screening were able to receive free medicines, potentially reducing the net between-group difference in blood pressure outcomes. This is evident from the control arm in India, which had >4 times the proportion of high-risk individuals on antihypertension treatment post intervention (17.9%) in comparison with preintervention (3.9%). These results from India were encouraging because they suggested that access to free medicine at the primary care setting had the potential to reap public health benefits.
We did not observe any significant changes for the lifestyle outcomes. This can be attributed to a number of factors. First, the implementation of the lifestyle intervention was not intensive. The CHWs were only required to provide lifestyle counseling on smoking cessation and salt reduction on a monthly basis in the intervention groups. Second, the intervention period of 12 months might be too short to observe meaningful changes in lifestyle. Last, despite cultural tailoring of lifestyle interventions, people (particularly >60 years of age) may be reluctant to change, and it is difficult for adults to change their long-held lifestyle habits.
Strengths and Limitations
To our knowledge, this was the first dual-country randomized, controlled trial to evaluate the effectiveness of a simplified CVD management program delivered by the CHWs with the aid of EDSS. To ensure the successful implementation of the trial, the study drew on the rich experiences of several directly related programs in China and India and also received strong government support from the local sites. The intervention model itself was designed with feasibility, acceptability, sustainability, and scalability in mind. In addition, the role of CHWs in this study was important, because their active engagement correlated with improved clinical outcomes. Last, the use of EDSS in our study has shed much needed light on the benefits of using mobile health technology in helping CHWs in resource-limited settings.
Our study has several limitations. First, the results of this study may not be generalizable to healthcare settings without existing or available CHWs, who played key roles in managing high-risk individuals in the SimCard trial. Second, this study was not able to evaluate the effectiveness of different components or specific measures of the simplified cardiovascular management program, eg, any given lifestyle modification or prescription of appropriate medication. However, our results on the lack of impact on lifestyle factors and the significant results on clinical care indicators suggested that the pharmaceutical components in the 2+2 model may have played a bigger role for the observed improvements. Third, the imbalances of 2 baseline characteristics (history of coronary heart disease and history of diabetes mellitus) in India could have potentially affected the outcome assessment. We did a further analysis by adjusting those 2 variables. The effect on the outcomes was small, with no change in the interpretation of the results.
Implications
Many regions in developing countries are now characterized as having triple burdens that include the longstanding problem of infectious diseases, the rapidly rising burden of noncommunicable chronic diseases, and the serious lack of economic and healthcare resources coupled with a weak healthcare system. 37, 38 Despite well-established national guidelines on chronic disease management, its uptake into routine clinical practice remains limited. A cost-effective, feasible, and culturally tailored approach is urgently needed in these areas that have high burdens of disease, but limited resources. Our simplified cardiovascular management program provides a framework on which the key components for effective CVD prevention and management can be based. These key components of the high-risk strategy include the following: effective, low-cost, and safe medications; lifestyle recommendations addressing the main risk factors for CVD; active involvement of CHWs; and an EDSS administered through customized mobile technology.
Our trial was conducted in 2 countries with both similarities and differences in healthcare systems and certain aspects of the implementation to adapt to local contexts and ethic requirements. The major driver of our outcome appears to be the enhanced use of drugs, whereas lifestyle changes did not influence the outcome in a significant way. The overall results demonstrated the effectiveness of the intervention model in improving the quality of clinical care at the primary care level, the potential lack of impact of this low-intensity primary caredelivered model on lifestyle behavioral changes, and the need to tailor the intervention and implementation to local settings.
The simplified cardiovascular management model tested in the SimCard study has the potential to be scaled up in more regions in China, India, and other countries to benefit a large number of disadvantaged populations. Larger context-specific trials are needed to enhance and refine the management program and to pinpoint the cost-effective components of the model. 
